On Monday, Sarepta Therapeutics got an upgrade to its Relative Strength (RS) Rating, from 70 to 77. This move is based on last market action from last week. Today, it is down slightly, hovering near the 200-day moving average.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of above 80 as they begin their largest climbs. See if Sarepta Therapeutics can continue to rebound and clear that threshold.
Looking For The Best Stocks To Buy And Watch? Start Here
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear a proper buy point.
SRPT Earnings
Sarepta Therapeutics posted 0% earnings growth last quarter, while sales growth came in at 12%. The company is expected to report its latest earnings and sales numbers on or around Nov. 1.
The company earns the No. 135 rank among its peers in the Medical-Biomed/Biotech industry group. HUTCHMED (China) ADR and Orchard Therapeutics ADR are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
